Events

Dementias 2026

dementias2026
Thank you for joining Roche Diagnostics at Dementias 2026.

The Dementias Conference 2026 served as a leading global forum dedicated to advancing the understanding, research, and innovation across the full spectrum of dementia and neurodegenerative diseases. The event brought together international experts, clinicians, researchers, and industry leaders to share the latest scientific insights, explore emerging solutions, and connect with peers from around the world.

From 25–26 February 2026, Roche was pleased to attend the conference and host an engaging symposium designed to foster meaningful discussion and collaboration. Our presence at the conference focused on deepening the collective understanding of dementia diagnosis as a critical first step toward earlier intervention, improved care pathways, and better outcomes for patients.

Thank you to everyone who joined us and visited the Roche activities. We appreciate the insightful dialogues and the shared commitment to transforming the future of dementia diagnosis.

Reflections on an Inspiring Symposium

dr ashton harper
peter berry

The power of knowing, a conversation with Peter Berry

On Wednesday, 25th February 2026, Roche Diagnostics hosted an insightful symposium titled "The power of knowing, a conversation with Peter Berry."

The session featured Dr. Ashton Harper, Global Medical Affairs Indication Lead for Neurosciences at Roche Diagnostics, in conversation with Peter Berry and his friend Deb Bunt. Together, they explored Peter’s personal journey from a period of diagnostic uncertainty to receiving an Alzheimer’s diagnosis.

The symposium highlighted the crucial clinical and personal impact of an earlier diagnosis, centred around the theme of "the power of knowing."

Key Takeaways from the Session:

  • The UK context: Attendees gained an understanding of the scale, pressure, and rising demand on memory services caused by an ageing population and the increasing prevalence of dementia.

  • The Challenge of Uncertainty: The discussion explored the difficulties clinicians face when diagnosing subtle early cognitive symptoms and how that uncertainty affects patient anxiety, key decision making, and the broader UK health system.

  • Roche’s Commitment: The session showcased how Roche Diagnostics is supporting clinicians through innovation, including CSF biomarker testing, the pTau181 rule-out blood test, and emerging innovations like pTau217, all designed to increase diagnostic confidence earlier in the patient pathway.

  • A Lived Experience: Peter Berry shared a first-hand account of living with diagnostic uncertainty and described how receiving a formal diagnosis ultimately provided him with a renewed sense of clarity and purpose.

Thank you to everyone who attended this session to gain a deeper understanding of the diagnostic pathway and the profound human impact of earlier diagnosis.

 

Register now to stay up to date with latest Neurology advances at Roche Diagnostics

At Dementias 2026 and beyond